FDA gives marketing approval for Enzymotec’s Cardiabeat

The company can state on the packaging that the product can help reduce risks of heart attacks.

Food and nutrition supplement company Enzymote Corporation has obtained US Food and Drug Administration (FDA) approval to market its product CadiaBeat as a product that can help reduce the risk of heat attacks. CardiaBeat was approved as a “new dietary ingredient”.

Any food supplement not in already use requires special FDA approval for marketing. Enzymotec also obtained approval to state on CardiaBeat’s packaging that it helps reduce the risk of heart attacks. The product has already been marketed for several months as a food supplement for reducing fats in yogurts, health food snacks and other foods.

CardiaBeat includes phytosterols, a substance that attaches to Omega-3 fatty acids. Enzymotec says CardiaBeat can reduce the number of risk factors in heart attacks by lowering blood cholesterol levels, among other things. A number of studies have recently been published in the US, which cast doubt on the effectiveness of Omega-3 fatty acids in preventing heart attacks, but the FDA found no reason to deny Enzymotec the right to make its claim about CardiaBeat.

Published by Globes [online], Israel business news - www.globes.co.il - on July 2, 2006

© Copyright of Globes Publisher Itonut (1983) Ltd. 2006

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018